Theodora Harold (T-Therapeutics)
Overview
Theodora Harold is a notable figure in the biotechnology industry, currently serving as the CEO of T-Therapeutics, a Cambridge-based biotech company. With over 25 years of experience, she has significantly influenced the biotech sector through her executive leadership and involvement in key business development ventures. Harold is recognized for her success in securing substantial funding and driving strategic growth in various companies. Before joining T-Therapeutics, she held pivotal roles at Crescendo Biologics, MISSION Therapeutics, and PsiOxus Therapeutics.
Recent Developments
In the past year, Theodora Harold has made significant strides in her leadership role at T-Therapeutics:
- November 2025: Under Harold’s leadership, T-Therapeutics successfully expanded its Series A financing to $91 million to advance their first-in-class bispecifics towards clinical trials. This milestone highlights the company’s progress in developing next-generation T cell receptor therapeutics for cancer and autoimmune diseases. (source)
- March 2025: Harold was appointed as the CEO of T-Therapeutics, succeeding founder Allan Bradley, who transitioned to the role of Chief Scientific Officer. This move was part of a strategic effort to progress the company’s therapeutic development capabilities. (source)
- 2025: T-Therapeutics launched its OpTiMus® platform, a significant innovation designed to address challenging TCR targets with advanced human binders, forming the basis for a new pipeline of therapeutic candidates. (source)
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Theodora Harold |
| Born | Unspecified |
| Nationality | British |
| Occupation | Chief Executive Officer at T-Therapeutics |
| Known For | Leadership in Biotech Sector |
| Net Worth | Not publicly disclosed |
| Education | University of Cambridge |
Early Life and Education
The early life details of Theodora Harold are largely undisclosed, however, her educational background is a testament to her dedication to excellence. Harold graduated from the University of Cambridge, where she studied Classics at Trinity College, which provided her a strong foundation in both analytical thinking and scientific understanding. Her qualifications as a Chartered Accountant from PricewaterhouseCoopers exhibit her diverse skill set, combining finance and strategic management, which she has effectively leveraged throughout her career in the biotech sector.
Career and Notable Achievements
Theodora Harold’s career is marked by strategic leadership roles and transformative impact in the biotech industry:
- Crescendo Biologics: As former CEO, Harold led the company through significant transitions, including steering a $790 million partnership deal with Takeda, showcasing her prowess in corporate growth and development.
- MISSION Therapeutics and PsiOxus Therapeutics: At these organizations, Harold was instrumental in their founding management teams, cultivating crucial frameworks for research and development.
- PricewaterhouseCoopers: Harold’s early career in corporate finance and accountancy contributed to her deep understanding of financial strategies, which she later applied to her roles in biotechnology.
Current Work and Impact
Currently, Theodora Harold leads T-Therapeutics in its mission to develop innovative treatments for cancer and autoimmune diseases using their proprietary OpTiMus® platform. Her leadership is critical in advancing the company’s pipeline of first-in-class therapeutics designed to tackle previously undruggable targets, aiming for clinical trials and broader therapeutic applicability. Harold’s work is contributing significantly to the potential eradication of numerous cancer types and autoimmune diseases, establishing a new frontier in medical treatment and patient care.
Conclusion
Theodora Harold’s journey in the biotech industry exemplifies effective leadership and innovation. Under her stewardship, T-Therapeutics is poised to make substantial contributions to medical science and patient care, setting a benchmark in the development of next-generation therapeutics. Her strategic vision and vast expertise continue to impact the sector significantly, shaping the future landscape of healthcare solutions.